PLRS -- Pluristem Life Systems, Inc.
Com ($0.00001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Pluristem Announces Evidence That PLX-I Cells Are Immune Privileged
NEW YORK, Jan 29, 2007 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced evidence that its PLX-I cells have proven to be immune privileged. PLX-I cells are Pluristem's first potential product dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood. PLX-I cells are mesenchymal stems cells obtained from the placenta and expanded by using Pluristem's proprietary 3D PluriX(TM) technology.
Immune privileged is defined as the absence or diminution of rejection when implanted into unmatched recipients. Being immune privileged, the PLX-1 cells carry significant positive implications in the development of Company products for a variety of degenerative, malignant and immune diseases. Additionally, this immune modulating property could prove important in treating or preventing immune reactions associated with transplantation.
Ora Burger PhD. V.P. of R&D at Pluristem states: "Our PLX-I cells possess immune privileged characteristics that can be used in the future for other applications involving transplantations. PLX-I cells posses these immune privileged characteristics without carrying the associated social stigmata of embryonic stem cells because PLX-I cells come from the placenta."
William R. Prather RPh, MD, Sr. V.P. Corporate Development notes: "Mesenchymal stem cells can differentiate into a range of different tissues types associated with the musculoskeletal system such as bone, cartilage, fat, muscle, tendon and ligament. Consequently, mesenchymal stem cells are considered to be multipotent. Additionally, some reports provide evidence of these cells plasticity or the ability of mesenchymal stem cells to traverse tissue boundaries and give rise to cells of a different non-musculoskeletal tissue, such as brain or liver cells. If this is the case, mesenchymal stem cells may be used to help treat a broad range of tissues affected by damage or disease. Allogeneic transplantation of mesenchymal stem cells between different individuals may also be possible as these cells appear to be immune privileged in that they are not necessarily rejected when implanted into unmatched recipients. The characteristic of these cells being immune privileged may enable Pluristem to be involved with new clinical applications with PLX-I."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation.
PLX-I, Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
www.pluristem.com |
